ArticleBMC complementary and alternative medicine2018
Fisetin and polymeric micelles encapsulating fisetin exhibit potent cytotoxic effects towards ovarian cancer cells.
Article in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Pooled it
- Role of Fisetin in the Mammalian Reproductive System.Veterinary sciences · 2026Review
- Review
- Exploration of Bioactive Compounds, Antioxidant and Antibacterial Properties, and Their Potential Efficacy Against HT29 Cell Lines inMarine drugs · 2025Article
- Natural compounds in ovarian cancer: mechanistic insights and therapeutic potential.Frontiers in pharmacology · 2025Review
- Modulation ofPeerJ · 2025Article
- Therapeutic Potential of Natural Compounds to Modulate WNT/β-Catenin Signaling in Cancer: Current State of Art and Challenges.International journal of molecular sciences · 2024Review
- Cubosomal nanoformulation increaseTherapeutic delivery · 2024Article
- A nanoscale natural drug delivery system for targeted drug delivery against ovarian cancer: action mechanism, application enlightenment and future potential.Frontiers in immunology · 2024Review
- PLGA-PEG-c(RGDfK)-IET nanobiotechnology · 2024Article
- Role of Fisetin in Selected Malignant Neoplasms in Women.Nutrients · 2023Review
- Fisetin-In Search of Better Bioavailability-From Macro to Nano Modifications: A Review.International journal of molecular sciences · 2023Review
- Current Update on Nanotechnology-Based Approaches in Ovarian Cancer Therapy.Reproductive sciences (Thousand Oaks, Calif.) · 2023Review
- Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment.Molecules (Basel, Switzerland) · 2022Review
- Fisetin-induced cell death in human ovarian cancer cell lines via zbp1-mediated necroptosis.Journal of ovarian research · 2022Article
- Diet-derived small molecules (nutraceuticals) inhibit cellular proliferation by interfering with key oncogenic pathways: an overview of experimental evidence in cancer chemoprevention.Biologia futura · 2022Review
- Biotechnological Applications and Health-Promoting Properties of Flavonols: An Updated View.International journal of molecular sciences · 2022Review
- Fisetin Deters Cell Proliferation, Induces Apoptosis, Alleviates Oxidative Stress and Inflammation in Human Cancer Cells, HeLa.International journal of molecular sciences · 2022Article
- Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe anti-tumor activities of Natural compounds and their derivatives are of great interest to pharmaceutical industries. Fisetin is one of prospective natural compounds in this regard but unfortunately with poor hydrophilicity.
methodsThe effects of unmodified and modified fisetin in cultured ovarian cancer cells were compared by transmission electronmicroscopy to determine apoptotic bodies, MTT assay to quantitate cell numbers, and fluorescence activated cell sorting analyse of various markers to determine the apoptotic state. In addition, the efficacy of fisetin and fisetin-micelles in vivo was determined by using immunocompromised mice. Apoptosis was measured by established markers using both western blot analysis and immunochemistry. Angiogenesis in a xenograft mouse model carring SKOV3 cells was evaluated by color Doppler ultrasound and immunohistochemistry.
resultMultiple lines of evidence indicated that fisetin and fisetin micelles induce apoptosis in ovarian cancer cells in a dose-dependent manner. Histological analysis, terminal deoxynucleotidyltransferase-mediated nick-end labeling assay, western blot, immunohistochemical detection and microvessel density detection demonstrated that fisetin and fisetin micelles induced increased tumor apoptosis, proliferation suppression and antiangiogenesis activities.
conclusionAs far as we know, the present study is the first time to demonstrate the potency of both fisetin and fisetin micelles inducing apoptosis in ovarian cancer cells. Further studies will be needed to validate the therapeutic potential of fisetin and fisetin micelles in ovarian cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.